Google Ramping Up Pharma & Life Sciences Activity
Google’s interest in healthcare is not new, the company has invested in dozens of healthcare startups in the past, and has more than doubled pharma investments in each of the last two years.
Move Inventory Faster. It Starts with the Label
This special report details how enterprise labeling significantly improves your supplier transactions, and by using a simple formula, you can calculate potential savings when you eliminate the relabeling process and reduce costly inventory.
- 7 Ways to Stay Compliant, Stay Competitive with Enterprise Labeling
- Loftware Offers Trek Flexible and Scalable Labeling Solution
- 6 Burning Questions on Chemical Labeling
- 5 Burning Questions on Automotive Labeling
- All Resources
The Leader in Enterprise Labeling: Accurate, consistent and flexible labeling for supply chain success. Loftware integrates proven solutions with your business processes to standardize mission-critical labeling. Loftware ensures that you can quickly and easily support complex, global and high volume…
- Company Quicklook
Google appears to be laying the groundwork for a future in pharmaceuticals.
It’s attacking this industry from two directions, including direct investments and internal development of pharma-targeted efforts.
Regarding the former, Google has made 17 deals to pharmaceutical startups in the past 3 years, all through its Google Ventures investment arm.
This is a shift given that from 2009-2014, the company only completed 7 deals.
Thus far in 2017, Google has already participated in 6 pharma deals via Google Ventures.
Recent first-time deals completed in 2017 include Fulcrum Therapeutics (gene therapy), Arsanis (anti-bacterials), Spero Therapeutics (anti-bacterials), and BlackThorn Therapeutics (neurobehavioral disorders).
Below is a chart showing Google’s investments into pharma companies since 2009.
The factors behind this surge of investment are two-fold.
- Through Verily and Calico, Google has begun to build out its own pharmaceutical pipeline and so it may seek strategic developmental partnerships with these startups.
- While Google’s healthcare acquisitions have been limited, most recently acquiring Lift Labs in 2014, the company may seek to acquire pharma startups for either their valuable IP or talent.
Google’s internal pharmaceutical pipeline is still in its very early stages.
Verily and Calico are both engaged in numerous partnerships with ambitious goals.
Examples include Calico’s partnership with C4 Therapeutics to develop therapeutics targeting protein degradation and Verily’s partnership with GlaxoSmithKline to develop implanted devices that treat disease by modulating electrical signals to peripheral nerves.